GlassScriptPhysician profile
Michele Rhoe
NPI 1548516149
$5,974.32
in general payments reported to CMS, 2019-2025
27 companies · $2,057 in 2025
The $2,057 reported for 2025 was more than what 91% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $825 · 2022: $842 · 2023: $872 · 2024: $1,378 · 2025: $2,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,958 · Education: $349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,958.43 |
| Education | $348.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,403.27 | 2021-2025 | Tremfya |
| Ucb, INC. | $639.44 | 2021-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $487.47 | 2021-2025 | Adbry |
| Janssen Scientific Affairs, LLC | $430.27 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $406.83 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $314.64 | 2021-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $302.47 | 2022-2025 | Sotyktu |
| Amgen INC. | $266.27 | 2022-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $203.18 | 2021-2025 | Blu-U, Odomzo |
| Arcutis Biotherapeutics, INC. | $201.55 | 2023-2025 | Zoryve |
| Incyte Corporation | $189.16 | 2022-2025 | Opzelura |
| Pfizer INC. | $176.45 | 2021-2025 | |
| Lilly USA, LLC | $165.85 | 2021-2025 | Ebglyss |
| Abbvie INC. | $165.43 | 2021-2025 | |
| Genzyme Corporation | $145.12 | 2021-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $108.36 | 2024-2025 | Vtama |
| Galderma Laboratories, L.P. | $62.07 | 2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.23 | 2023-2025 | Spevigo |
| Dermavant Sciences, INC. | $43.39 | 2023-2024 | Vtama |
| Mallinckrodt Hospital Products INC. | $36.15 | 2024 | Acthar |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $35.95 | 2021-2025 | Cabtreo, Jublia, Siliq |
| Lnhc, INC | $34.65 | 2025 | Zelsuvmi |
| Verrica Pharmaceuticals INC. | $34.05 | 2023 | Ycanth |
| Almirall LLC | $21.14 | 2021 | |
| Blueprint Medicines Corporation | $18.66 | 2025 | Ayvakit |
| Ani Pharmaceuticals, INC. | $18.62 | 2022 | |
| Biofrontera INC. | $15.65 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Rhoe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.